Screening of Beta-Secretase Inhibitors by Capillary Electrophoresis-Mass Spectrometry

SCHEJBAL, Jan; Roman ŘEMÍNEK a Zdeněk GLATZ. Screening of Beta-Secretase Inhibitors by Capillary Electrophoresis-Mass Spectrometry. In Targeting Enzymes for Pharmaceutical Development: Methods and Protocols. TOTOWA: HUMANA PRESS INC, 2026.

Základní údaje

Originální název

Screening of Beta-Secretase Inhibitors by Capillary Electrophoresis-Mass Spectrometry

Autoři

SCHEJBAL, Jan; Roman ŘEMÍNEK a Zdeněk GLATZ

Vydání

TOTOWA, Targeting Enzymes for Pharmaceutical Development: Methods and Protocols, 2026

Nakladatel

HUMANA PRESS INC

---

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ne

UT WoS

000650966200010

Klíčová slova anglicky

Capillary electrophoresis; Mass spectrometry; Alzheimer's disease; Beta-secretase; Enzyme inhibition; Screening

---

Anotace

V originále

Alzheimer's disease is the most common cause of dementia, currently afflicting almost 40 million patients worldwide. According to the amyloid cascade hypothesis, the pathogenesis of the disease could be slowed down or even stopped by the inhibition of beta-secretase, making this aspartic acid protease a potentially important drug target site. Capillary electrophoresis is a promising technique for screening putative enzyme inhibitors due to highly effective separations, minuscule sample and other chemicals consumption, compatibility with a variety of detection techniques, and high throughput via automation. This chapter presents a method based on capillary electrophoresis coupled to mass spectrometry detection for kinetic and inhibition assays of the beta-secretase reaction with a decapeptide derived from an amyloid precursor protein.